Diabetes, Vol 44, Issue 12 1375-1380, Copyright © 1995 by American Diabetes Association

ARTICLES

NIDDM is the major cause of diabetic end-stage renal disease. More evidence from a tri-ethnic community

JA Pugh, RA Medina, JC Cornell and S Basu
University of Texas Health Science Center at San Antonio, USA.

Diabetes is the single largest cause of end-stage renal disease (ESRD) in adults in the U.S. Insulin-dependent diabetes mellitus (IDDM) has been recognized for some time as an important cause of ESRD, but non-insulin-dependent diabetes mellitus (NIDDM) has been assumed, until recently, to rarely cause ESRD. The objective of this study is to determine the incidence of treatment of diabetic ESRD by diabetic type for three ethnic/racial groups: non-Hispanic whites, African-Americans, and Mexican-Americans. A population-based incidence cohort was assembled from all dialysis centers in Bexar (San Antonio) and Dallas counties in Texas. All patients with diabetic ESRD beginning dialysis between 1 December 1987 (Bexar) or 1 December 1988 (Dallas) and 31 July 1991 were identified. All non-hispanic whites and African-Americans and a 1/2 random sample of Mexican-Americans were approached for enrollment. Individuals were confirmed to have diabetes using the World Health Organization criteria. Diabetes typing was done using a computerized historical algorithm. Age-specific and age-adjusted incidence rates were obtained by diabetic type and ethnic/racial group. NIDDM causes the majority of diabetic ESRD: 59.5% for non-Hispanic whites, 92.8% for Mexican-Americans, and 84.3% for African-Americans. Mexican-Americans and African-Americans, respectively, have 6.1 and 6.5 times higher incidence of treatment for diabetic ESRD than non-Hispanic whites. NIDDM results in more ESRD than does IDDM. Minorities (African-Americans and Mexican-Americans) are at increased risk, and programs aimed at prevention of NIDDM-related ESRD must focus on them.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				B. A. Young, W. J. Katon, M. Von Korff, G. E. Simon, E. H. B. Lin, P. S. Ciechanowski, T. Bush, M. Oliver, E. J. Ludman, and E. J. Boyko Racial and Ethnic Differences in Microalbuminuria Prevalence in a Diabetes Population: The Pathways Study J. Am. Soc. Nephrol., January 1, 2005; 16(1): 219 - 228. [Abstract] [Full Text] [PDF]

				C. E. Lok, M. J. Oliver, D. M. Rothwell, and J. E. Hux The growing volume of diabetes-related dialysis: a population based study Nephrol. Dial. Transplant., December 1, 2004; 19(12): 3098 - 3103. [Abstract] [Full Text] [PDF]

				S. Nomura, A. Shouzu, S. Omoto, M. Nishikawa, and T. Iwasaka Effects of Losartan and Simvastatin on Monocyte-Derived Microparticles in Hypertensive Patients With and Without Type 2 Diabetes Mellitus Clinical and Applied Thrombosis/Hemostasis, April 1, 2004; 10(2): 133 - 141. [Abstract] [PDF]

				M. B. Davidson Effect of Nurse-Directed Diabetes Care in a Minority Population Diabetes Care, August 1, 2003; 26(8): 2281 - 2287. [Abstract] [Full Text] [PDF]

				G. Bruno, A. Biggeri, F. Merletti, G. Bargero, S. Ferrero, G. Pagano, and P. C. Perin Low Incidence of End-Stage Renal Disease and Chronic Renal Failure in Type 2 Diabetes: A 10-year prospective study Diabetes Care, August 1, 2003; 26(8): 2353 - 2358. [Abstract] [Full Text] [PDF]

				B. A. Young, C. Maynard, and E. J. Boyko Racial Differences in Diabetic Nephropathy, Cardiovascular Disease, and Mortality in a National Population of Veterans Diabetes Care, August 1, 2003; 26(8): 2392 - 2399. [Abstract] [Full Text] [PDF]

				M. E. Molitch, W. Fujimoto, R. F. Hamman, and W. C. Knowler The Diabetes Prevention Program and Its Global Implications J. Am. Soc. Nephrol., July 1, 2003; 14(90002): S103 - 107. [Abstract] [Full Text] [PDF]

				D. L. Frankenfield, M. V. Rocco, S. H. Roman, and W. M. McClellan Survival Advantage for Adult Hispanic Hemodialysis Patients? Findings from the End-Stage Renal Disease Clinical Performance Measures Project J. Am. Soc. Nephrol., January 1, 2003; 14(1): 180 - 186. [Abstract] [Full Text] [PDF]

				R. R. McCandless Attributing Inpatient Medicare Costs to Diabetes Among the Texas Elderly Diabetes Care, November 1, 2002; 25(11): 1958 - 1963. [Abstract] [Full Text] [PDF]

				G. Viberti, N. M. Wheeldon, and for the MicroAlbuminuria Reduction With VALsartan Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure-Independent Effect Circulation, August 6, 2002; 106(6): 672 - 678. [Abstract] [Full Text] [PDF]

				A. J. Karter, A. Ferrara, J. Y. Liu, H. H. Moffet, L. M. Ackerson, and J. V. Selby Ethnic Disparities in Diabetic Complications in an Insured Population JAMA, May 15, 2002; 287(19): 2519 - 2527. [Abstract] [Full Text] [PDF]

				M. B. Davidson, V. J. Karlan, and T. L. Hair Effect of a Pharmacist-Managed Diabetes Care Program in a Free Medical Clinic American Journal of Medical Quality, July 1, 2000; 15(4): 137 - 142. [Abstract] [PDF]

				D. J. CORDONNIER, N. PINEL, C. BARRO, C. MAYNARD, P. ZAOUI, S. HALIMI, B. H. DE LIGNY, Y. REZNIC, D. SIMON, and R. W. BILOUS Expansion of Cortical Interstitium Is Limited by Converting Enzyme Inhibition in Type 2 Diabetic Patients with Glomerulosclerosis J. Am. Soc. Nephrol., June 1, 1999; 10(6): 1253 - 1263. [Abstract] [Full Text]